Traumatic Brain Injury – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Traumatic Brain Injury – Pipeline Review, H2 2018’, provides an overview of the Traumatic Brain Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury

– The report reviews pipeline therapeutics for Traumatic Brain Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Traumatic Brain Injury therapeutics and enlists all their major and minor projects

– The report assesses Traumatic Brain Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Traumatic Brain Injury

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALSP Inc

Amarantus Bioscience Holdings Inc

Aptinyx Inc

Athersys Inc

Avanir Pharmaceuticals Inc

Biogen Inc

CalciMedica Inc

Cantex Pharmaceuticals Inc

Cognosci Inc

Complement Pharma BV

Eisai Co Ltd

Epigen Biosciences Inc

Eustralis Pharmaceuticals Ltd

Hoverink Biotechnologies Inc

Intellect Neurosciences Inc

International Stem Cell Corp

Ischemix Inc

JT Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Levolta Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

Mapreg SAS

Neuralstem Inc

Neuren Pharmaceuticals Ltd

Neurofx Inc

NeuroNascent Inc

NeuroVive Pharmaceutical AB

New World Laboratories Inc

NoNO Inc

Noxopharm Ltd

NuvOx Pharma LLC

Oxeia Biopharmaceuticals Inc

Prevacus Inc

QR Pharma Inc

RegeneRx Biopharmaceuticals Inc

Resolys Bio Inc

Rubicon Biotechnology Inc

Sage Therapeutics Inc

SanBio Inc

Scythian Biosciences Corp

Silver Creek Pharmaceuticals Inc

STATegics Inc

Stemedica Cell Technologies Inc

SynZyme Technologies LLC

Tetra Discovery Partners LLC

Therapix Biosciences Ltd

Tiziana Life Sciences Plc

vasopharm GmbH

VG Life Sciences Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Traumatic Brain Injury Overview 6

Traumatic Brain Injury Therapeutics Development 7

Traumatic Brain Injury Therapeutics Assessment 20

Traumatic Brain Injury Companies Involved in Therapeutics Development 32

Traumatic Brain Injury Drug Profiles 51

Traumatic Brain Injury Dormant Projects 279

Traumatic Brain Injury Discontinued Products 283

Traumatic Brain Injury Product Development Milestones 284

Appendix 295

List of Tables

List of Tables

Number of Products under Development for Traumatic Brain Injury, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Traumatic Brain Injury Pipeline by ALSP Inc, H2 2018

Traumatic Brain Injury Pipeline by Amarantus Bioscience Holdings Inc, H2 2018

Traumatic Brain Injury Pipeline by Aptinyx Inc, H2 2018

Traumatic Brain Injury Pipeline by Athersys Inc, H2 2018

Traumatic Brain Injury Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Traumatic Brain Injury Pipeline by Biogen Inc, H2 2018

Traumatic Brain Injury Pipeline by CalciMedica Inc, H2 2018

Traumatic Brain Injury Pipeline by Cantex Pharmaceuticals Inc, H2 2018

Traumatic Brain Injury Pipeline by Cognosci Inc, H2 2018

Traumatic Brain Injury Pipeline by Complement Pharma BV, H2 2018

Traumatic Brain Injury Pipeline by Eisai Co Ltd, H2 2018

Traumatic Brain Injury Pipeline by Epigen Biosciences Inc, H2 2018

Traumatic Brain Injury Pipeline by Eustralis Pharmaceuticals Ltd, H2 2018

Traumatic Brain Injury Pipeline by Hoverink Biotechnologies Inc, H2 2018

Traumatic Brain Injury Pipeline by Intellect Neurosciences Inc, H2 2018

Traumatic Brain Injury Pipeline by International Stem Cell Corp, H2 2018

Traumatic Brain Injury Pipeline by Ischemix Inc, H2 2018

Traumatic Brain Injury Pipeline by JT Pharmaceuticals Inc, H2 2018

Traumatic Brain Injury Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Traumatic Brain Injury Pipeline by Levolta Pharmaceuticals Inc, H2 2018

Traumatic Brain Injury Pipeline by Lixte Biotechnology Holdings Inc, H2 2018

Traumatic Brain Injury Pipeline by Mapreg SAS, H2 2018

Traumatic Brain Injury Pipeline by Neuralstem Inc, H2 2018

Traumatic Brain Injury Pipeline by Neuren Pharmaceuticals Ltd, H2 2018

Traumatic Brain Injury Pipeline by Neurofx Inc, H2 2018

Traumatic Brain Injury Pipeline by NeuroNascent Inc, H2 2018

Traumatic Brain Injury Pipeline by NeuroVive Pharmaceutical AB, H2 2018

Traumatic Brain Injury Pipeline by New World Laboratories Inc, H2 2018

Traumatic Brain Injury Pipeline by NoNO Inc, H2 2018

Traumatic Brain Injury Pipeline by Noxopharm Ltd, H2 2018

Traumatic Brain Injury Pipeline by NuvOx Pharma LLC, H2 2018

Traumatic Brain Injury Pipeline by Oxeia Biopharmaceuticals Inc, H2 2018

Traumatic Brain Injury Pipeline by Prevacus Inc, H2 2018

Traumatic Brain Injury Pipeline by QR Pharma Inc, H2 2018

Traumatic Brain Injury Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2018

Traumatic Brain Injury Pipeline by Resolys Bio Inc, H2 2018

Traumatic Brain Injury Pipeline by Rubicon Biotechnology Inc, H2 2018

Traumatic Brain Injury Pipeline by Sage Therapeutics Inc, H2 2018

Traumatic Brain Injury Pipeline by SanBio Inc, H2 2018

Traumatic Brain Injury Pipeline by Scythian Biosciences Corp, H2 2018

Traumatic Brain Injury Pipeline by Silver Creek Pharmaceuticals Inc, H2 2018

Traumatic Brain Injury Pipeline by STATegics Inc, H2 2018

Traumatic Brain Injury Pipeline by Stemedica Cell Technologies Inc, H2 2018

Traumatic Brain Injury Pipeline by SynZyme Technologies LLC, H2 2018

Traumatic Brain Injury Pipeline by Tetra Discovery Partners LLC, H2 2018

Traumatic Brain Injury Pipeline by Therapix Biosciences Ltd, H2 2018

Traumatic Brain Injury Pipeline by Tiziana Life Sciences Plc, H2 2018

Traumatic Brain Injury Pipeline by vasopharm GmbH, H2 2018

Traumatic Brain Injury Pipeline by VG Life Sciences Inc, H2 2018

Traumatic Brain Injury Dormant Projects, H2 2018

Traumatic Brain Injury Dormant Projects, H2 2018 (Contd..1), H2 2018

Traumatic Brain Injury Dormant Projects, H2 2018 (Contd..2), H2 2018

Traumatic Brain Injury Dormant Projects, H2 2018 (Contd..3), H2 2018

Traumatic Brain Injury Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Traumatic Brain Injury, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports